Tag: NOXA12
TME Pharma: FDA Grants Fast Track Designation for NOX-A12
(Boursier.com) — TME Pharmaa biotechnology company specializing in the development of new therapies for the treatment of cancer by targeting the tumor microenvironment (TME), announces that the US Food and…
TME PHARMA – The US FDA grants Fast Track designation for NOX-A12, TME Pharma’s lead program, in brain cancer – 04/02/2024 at 8:30 p.m.
TME Pharma NV (Euronext Growth Paris: ALTME), a biotechnology company specializing in the development of novel therapies for the treatment of cancer by targeting the tumor microenvironment (TME), announces that…
TME PHARMA ANNOUNCES THE SUCCESS OF ADVISORY MEETING WITH THE US FDA ON THE DEVELOPMENT OF NOX-A12 IN BRAIN CANCER – 01/09/2024 at 6:00 p.m.
• A constructive meeting with the FDA provided feedback and clear guidance on key aspects of the continued development of NOX-A12 combinations for the treatment of glioblastoma.• Preparatory work is…
TME Pharma: constructive meeting with the FDA for NOX-A12 – 01/09/2024 at 6:18 p.m.
(AOF) – TME Pharma announces the success of the advisory meeting with the FDA on the development of NOX-A12 against brain cancer. Based on the information received, TME Pharma confirms…
TME Pharma: constructive meeting with the FDA for NOX-A12
(AOF) – TME Pharma announces the success of the advisory meeting with the FDA on the development of NOX-A12 against brain cancer. Based on the information received, TME Pharma confirms…
TME PHARMA ANNOUNCES THE PRESENTATION OF ADDITIONAL DATA ON COMBINATION TREATMENT OF NOX-A12 IN BRAIN CANCER AT THE SNO 2023 ANNUAL MEETING – 11/18/2023 at 08:00
TME PHARMA ANNOUNCES PRESENTATION OF ADDITIONAL DATA ON COMBINATION TREATMENT OF NOX-A12 IN BRAIN CANCER AT SNO 2023 ANNUAL MEETING • Substantial improvement in survival and progression-free survival in NOX-A12…
TME Pharma: the FDA accepts a new clinical trial for Nox-A12 – 06/15/2023 at 18:24
(AOF) – TME Pharma announces today that after a complete review of the dossier submitted to it, the American Food and Drug Administration (FDA) has approved the request to launch…
TME PHARMA PRESENTS CLINICAL UPDATE ON GLORIA EXPANSION ARM TESTING NOX-A12 IN COMBINATION WITH RADIOTHERAPY AND BEVACIZUMAB IN PATIENTS WITH GLIOBLASTOMA – 01/23/2023 at 08:00
• With a median follow-up of 10 months to date, 5 of 6 patients remain alive. • Follow-up continues as median overall survival has not yet been reached. Berlin, Germany,…
PRESENTATION OF UPDATED POSITIVE INTERIM RESULTS OF NOX-A12 GLORIA PHASE 1/2 IN BRAIN CANCER AT THE 2022 ANNUAL MEETING OF THE SOCIETY FOR NEURO-ONCOLOGY (SNO) – 11/19/2022 at 01: 30
• 100% radiographic partial response rate achieved in patients treated with NOX A12 + radiotherapy + bevacizumab. 83% of patients show durable mRANO responses.• Of the 6 patients treated, 2…
Confirmation of the safety of the combination of NOX-A12 and pembrolizumab in the GLORIA phase 1/2 study in brain cancer – 08/26/2022 at 08:00
To receive all of the company’s financial communications in real time, please register directly by email at the following address: [email protected] Berlin, Germany, August 26, 2022, 08:00 CEST – TME…
NOXXON Presents Key Data from Phase 1/2 GLORIA Study Evaluating NOX-A12 in Glioblastoma at ASCO 2022 Annual Meeting – 06/05/2022 at 15:00
To receive all the news in real time from NOXXON, please contact [email protected] Berlin, Germany, June 5, 2022, 3:00 p.m. CEST – NOXXON Pharma NV (Euronext Growth Paris: ALNOX), a…
NOXXON provides an update on the evaluation of NOX-A12 in a non-oncological indication by a large international pharmaceutical laboratory – 01/05/2022 at 19:30
To receive all Noxxon news in real time, contact [email protected] Berlin, Germany, January 5, 2022, 7:30 p.m. CET – NOXXON Pharma NV (Euronext Growth Paris: ALNOX), a biotechnology company specializing…